Cargando…

Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small‐cell lung cancer

The transformation from non‐small‐cell lung cancer (NSCLC) to small‐cell lung cancer (SCLC) is one of the mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) resistance. Previous studies exhibited that the median transformation time was 17.8 months for NSCLC to SCLC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hao, Lidan, Chen, Haiyang, Wang, Lili, Zhou, Hanqiong, Zhang, Zhe, Han, Jing, Hou, Jiabao, Zhu, Yichen, Zhang, He, Wang, Qiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101832/ https://www.ncbi.nlm.nih.gov/pubmed/36810856 http://dx.doi.org/10.1111/1759-7714.14832

Ejemplares similares

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
por: Hou, Jiabao, et al.
Publicado: (2022)

Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer
por: Samulin Erdem, Johanna, et al.
Publicado: (2016)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2016)

Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review
por: Zhang, Zhe, et al.
Publicado: (2021)

Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers
por: Li, Jun, et al.
Publicado: (2022)

A Pan-Cancer Assessment of RB1/TP53 Co-Mutations
por: Cai, Ling, et al.
Publicado: (2022)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
por: Wu, Chih‐Hsun, et al.
Publicado: (2019)

Study of polymorphisms in the TP53 and RB1 genes in children with retinoblastoma in northern Mexico
por: Anaya-Pava, Edwin J., et al.
Publicado: (2017)

Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma
por: Saghaeiannejad Esfahani, Hoda, et al.
Publicado: (2021)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

Reporting quality of clinical practice guidelines on head and neck cancer: a systematic review
por: Hou, Jiabao, et al.
Publicado: (2022)

Frequent Mutations in EGFR, KRAS and TP53 Genes in Human Lung Cancer Tumors Detected by Ion Torrent DNA Sequencing
por: Cai, Xin, et al.
Publicado: (2014)

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
por: Sun, Haiyan, et al.
Publicado: (2023)

Coexisting EGFR and TP53 Mutations in Lung Adenocarcinoma Patients Are Associated With COMP and ITGB8 Upregulation and Poor Prognosis
por: Zheng, Chang, et al.
Publicado: (2020)

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
por: Canale, Matteo, et al.
Publicado: (2022)

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
por: Liu, Surui, et al.
Publicado: (2022)

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
por: Niederst, Matthew J., et al.
Publicado: (2015)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

Concordance of Abundance for Mutational EGFR and Co-Mutational TP53 with Efficacy of EGFR-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer
por: Wang, Youping, et al.
Publicado: (2023)

Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer
por: Liu, Yutao, et al.
Publicado: (2019)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Interaction between the microbiome and TP53 in human lung cancer
por: Greathouse, K. Leigh, et al.
Publicado: (2018)

The anti‐metastatic effect of ginsenoside Rb2 in colorectal cancer in an EGFR/SOX2‐dependent manner
por: Phi, Lan Thi Hanh, et al.
Publicado: (2018)

TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Le, Xiuning, et al.
Publicado: (2022)

Involvement of TP53 and TP16 expression in human papillomavirus-associated non-small cell lung cancer
por: Li, Ming, et al.
Publicado: (2016)

Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma
por: Beird, Hannah C., et al.
Publicado: (2023)

Differential Expression of ID4 and Its Association with TP53 Mutation, SOX2, SOX4 and OCT-4 Expression Levels
por: Galatro, Thais Fernanda de Almeida, et al.
Publicado: (2013)

Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
por: Liu, Shui, et al.
Publicado: (2022)

Quantitative Analysis of TP53-Related Lung Cancer Based on Radiomics
por: Qiao, Hongyu, et al.
Publicado: (2022)

Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2015)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study
por: Syahruddin, Elisna, et al.
Publicado: (2022)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report
por: Ma, Shuxiang, et al.
Publicado: (2020)

T antigen transformation reveals Tp53/RB-dependent route to PLAC1 transcription activation in primary fibroblasts
por: Chen, Y, et al.
Publicado: (2013)

Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish
por: Luo, Juanjuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vl1dtbljosjl88pmf92khobkqc